Biovista will identify novel repositioning candidates while DART Therapeutics will have the option to select a certain number for further development, according to the agreement.
DART Therapeutics CEO Gene Williams said that drug repositioning is the major approach in the company’s overall strategy to identify novel treatments for DMD.
"Biovista and the COSS technology are leaders in systematic repositioning, ensuring for us the broadest possible coverage of repositioning opportunities that can have real impact for patients and their families awaiting treatment for DMD," Williams added.
The terms of the agreement include upfront and downstream success payments.
Biovista president Aris Persidis said, "We believe that these types of collaborations are indicative of stakeholders looking to develop therapies in a novel manner that more directly addresses their specific needs, and we look forward to working with DART Therapeutics."